Our results demonstrated that serum levels of IL-6 and sIL-6R remained significantly elevated in COVID-19 patients compared to healthy controls (54.05 ± 16.5 pg/mL vs. 1.95 ± 0.91 pg/mL, p < 0.01 and 53.83 ± 12.29 ng/mL vs. 30.51 ± 8.18 ng/mL, p < 0.05, respectively), whereas levels of the antagonist sgp130 returned to those of the controls (361.67 ± 45.14 ng/mL vs. 298 ± 25.02 ng/mL) (Figure 4). This evidence concerns the gene IL6R and COVID-19.